Condition: VEXAS Syndome · Myelo Dysplastic Syndrome · Sponsor: Groupe Francophone des Myelodysplasies
Multicenter, phase II trial with safety run-in to evaluate the efficacy and safety of momelotinib in patients with VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome with or without associated myelodysplastic syndrome (MDS). The study will consist of two consecutive steps, a dose-finding safety run-in and a single-arm prospective phase II. During safety run-in phase, three fixed dose levels will be tested according to a 3+3 design, using cohorts of size 3 in order to establish the maximum tolerated dose. After this safety run-in phase, patients included in phase II will be treated with momelotinib at the maximum tolerated dose preliminary fixed. Patients included in the phase II will receive momelotinib continuously until disease progression or loss of response, at physician's discretion. All patients included in the study will receive glucocorticoids (prednisone/prednisolone equivalent) at baseline (at least \> 10mg/day). Response assessment regarding VEXAS related symptoms will be evaluated after 4, 12, 24 and 48 weeks. Response assessment regarding MDS features will be evaluated at 12 and 24 weeks.
This description comes directly from the study's public registry record.
Maël HEIBLIG, MD · +33 4 72 11 74 01 · mael.heiblig@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| CHU d'Angers - Service des Maladies du sang | Angers, France | Not Yet Recruiting |
| CHU Estaing - Service d'Hématologie Clinique | Clermont-Ferrand, France | Not Yet Recruiting |
| Hôpital Claude Huriez - Service de Médecine Interne | Lille, France | Not Yet Recruiting |
| CHU Nantes - Hôtel Dieu - Service d'Hématologie Clinique | Nantes, France | Not Yet Recruiting |
| Hôpital Saint Louis - Service hématologie séniors | Paris, France | Not Yet Recruiting |
| Hôpital Saint-Antoine - Service de Médecine Interne | Paris, France | Not Yet Recruiting |
| CHU de Haut-Lévèque - Centre F. Magendie - Service des Maladies du sang | Pessac, France | Not Yet Recruiting |
| CH Lyon sud - Service d'Hématologie Clinique | Pierre-Bénite, France | Recruiting |
| Hôpital Pontchaillou Service d'hématologie clinique et service de médecine interne | Rennes, France | Not Yet Recruiting |
| IUCT Oncopole Département d'hématologie / Unité de médecine interne | Toulouse, France | Not Yet Recruiting |
| CHU de Tours - Hôpital Bretonneau - Service de Médecine Interne | Tours, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07098936